Lo Andrew

Director Lo Andrew sold 95,599 shares of BBIO for $6.3M across 4 transactions on Nov 17-18; post-transaction holdings dropped 65.4% to 50,583 shares.

Andrew Lo, a Director, executed four separate sales totaling 95,599 shares for $6,319,662.44 at blended average price $66.11 over two trading days (Nov 17-18). The sale reduced his holdings by 65.4%, from 146,182 shares to 50,583 shares. The transaction occurred near the 52-week high ($66.90, currently -2.0% away), during a period when the stock has rallied +16.5% over 30 days and +30.5% over 90 days. Across his cross-ticker open-market history, Lo's prior sells have averaged a +22.8% 90-day return (poorly timed, as the stock rose after), with a 0.00% well-timed rate. At BridgeBio specifically, his single prior sale on 2025-05-02 also posted a +22.8% 90-day return. The company remains unprofitable (net income $-184,937,000.00 on revenue of $120,700,000.00) despite explosive annual revenue growth of +2285.3%.

Director Andrew Lo sold 100,000 shares of BBIO at $38.50 on 2025-05-02, reducing holdings by 48.6% to 105,583 shares.

Director Andrew Lo sold 100,000 shares at $38.50, representing a substantial reduction of 48.6% of his pre-transaction holdings of 205,583 shares. The sale occurred at $38.50, near the 52-week high of $38.57, and the stock has since declined 4.2% to a current price of $36.94. BridgeBio is an unprofitable company with net income of $-169,608,000.00 in its most recent fiscal year, though it reported strong revenue growth of 2285.3% year-over-year to $116,633,000.00 in the latest quarter. The substantial equity reduction by a director at elevated valuation levels in an unprofitable biotech company, combined with the stock's subsequent decline from the sale price, merits investor attention to the company's clinical and commercial execution.